Serum lipid profile due to risperidone treatment in child and youth patients

Basit Öğe Kaydı
dc.contributor.authorKaraman, Mehmet Gökşin
dc.contributor.authorYurteri, Nihal
dc.contributor.authorÖzdemir, Esra
dc.contributor.authorKala, Serhat
dc.contributor.authorAnkaralı, Handan
dc.contributor.authorElmacı, Figen Karaman
dc.contributor.authorErdoğan, Ayten
dc.date.accessioned2020-04-30T23:31:53Z
dc.date.available2020-04-30T23:31:53Z
dc.date.issued2011
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.descriptionAnkarali, Handan Camdeviren/0000-0002-3613-0523en_US
dc.descriptionWOS: 000297870000008en_US
dc.description.abstractObjective: Atypical antipsychotics (AAPs) have been reported to cause metabolic dysregulation that may result in AAPs-related weight gain. The purpose of this study was to assess triglyceride, cholesterol and weight changes among risperidone-treated child and youths. Methods: Eighty subjects treated with risperidone for any psychiatric disturbances were included in the study. Fasting total low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, (HDL-C), total cholesterol (TC), and triglyceride (TG) levels were measured at baseline and at 12 months of treatment. Results: There was no significant difference between baseline mean levels of TG, TC, HDL-C and LDL-C and twelfth months mean levels of TG, TC, HDL-C and LDL-C (respectively p=0.341, p=0.135, p=0.414, p=0.411, p=0.707). Comparison of baseline and 12 months data with respect to the age groups were presented in table 2. There was no significant association with age, gender, risperidone dose and changes of serum TG, TC, LDL-C or HDL-C levels. Conclusion: In conclusion, this study did not identify significant associations between dyslipidemia and one year risperidone treatment in children and adolescents. Because little long-term lipid profile follow-up is available with atypical antipsychotics treatment in youths, controlled studies in larger samples should be carried out to reveal the frequency and the risk factors of dyslipidemia. (Anatolian Journal of Psychiatry 2011; 12:295-300)en_US
dc.identifier.endpage300en_US
dc.identifier.issn1302-6631
dc.identifier.issue4en_US
dc.identifier.startpage295en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4515
dc.identifier.volume12en_US
dc.identifier.wosWOS:000297870000008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherCumhuriyet Univ Tip Fak Psikiyatri Anabilim Dalien_US
dc.relation.ispartofAnadolu Psikiyatri Dergisi-Anatolian Journal Of Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectatypical antipsychoticen_US
dc.subjectrisperidoneen_US
dc.subjectchilden_US
dc.subjecttriglycerideen_US
dc.subjectlipid profileen_US
dc.titleSerum lipid profile due to risperidone treatment in child and youth patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu